Some evidence suggests that a variety of markers are indicative of the outcome of SFTS patients, such as the C-reactive protein (CRP)–to–albumin ratio (CAR),7 the platelet-to-albumin ratio (PAR),8 and the aggregate index of systemic inflammation (AISI), which represents immunological and inflammatory status as well as the associated infectious disease risk and mortality.9 This evidence concerns the gene ALB and infectious disease.